The massive ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 but likely spreading since February, dominates trader focus for 2026 case markets. It has already produced thousands of confirmed infections and deaths across six provinces, fueled by high population mobility through mining areas and conflict zones, limited contact tracing, and the absence of approved vaccines or treatments tailored to this strain. Imported cases have surfaced in Uganda (20 total, outbreak declared over by late July) and France (one), with treatment links to Germany, underscoring cross-border risks to neighbors like South Sudan. Rapid case growth and incomplete detection mean new reports from additional countries remain possible before year-end, though response efforts and surveillance upgrades could limit further spread.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$34,139 Vol.
Dec 30, 2026
South Sudan
65%
Rwanda
28%
Burundi
29%
United States
23%
Canada
23%
Kenya
52%
India
14%
Republic of the Congo
27%
Nigeria
17%
Ethiopia
51%
Somalia
35%
China
18%
$34,139 Vol.
South Sudan
$2,063 Vol.
65%
Rwanda
$2,128 Vol.
28%
Burundi
$200 Vol.
29%
United States
$10,195 Vol.
23%
Canada
$1,102 Vol.
23%
Kenya
$195 Vol.
52%
India
$732 Vol.
14%
Republic of the Congo
$12,170 Vol.
27%
Nigeria
$25 Vol.
17%
Ethiopia
$65 Vol.
51%
Somalia
$71 Vol.
35%
China
$3,239 Vol.
18%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The massive ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 but likely spreading since February, dominates trader focus for 2026 case markets. It has already produced thousands of confirmed infections and deaths across six provinces, fueled by high population mobility through mining areas and conflict zones, limited contact tracing, and the absence of approved vaccines or treatments tailored to this strain. Imported cases have surfaced in Uganda (20 total, outbreak declared over by late July) and France (one), with treatment links to Germany, underscoring cross-border risks to neighbors like South Sudan. Rapid case growth and incomplete detection mean new reports from additional countries remain possible before year-end, though response efforts and surveillance upgrades could limit further spread.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Market Opened: May 22, 2026, 12:35 PM ET
Volume
$34,139End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The massive ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 but likely spreading since February, dominates trader focus for 2026 case markets. It has already produced thousands of confirmed infections and deaths across six provinces, fueled by high population mobility through mining areas and conflict zones, limited contact tracing, and the absence of approved vaccines or treatments tailored to this strain. Imported cases have surfaced in Uganda (20 total, outbreak declared over by late July) and France (one), with treatment links to Germany, underscoring cross-border risks to neighbors like South Sudan. Rapid case growth and incomplete detection mean new reports from additional countries remain possible before year-end, though response efforts and surveillance upgrades could limit further spread.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volume
$34,139End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...The massive ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared in May 2026 but likely spreading since February, dominates trader focus for 2026 case markets. It has already produced thousands of confirmed infections and deaths across six provinces, fueled by high population mobility through mining areas and conflict zones, limited contact tracing, and the absence of approved vaccines or treatments tailored to this strain. Imported cases have surfaced in Uganda (20 total, outbreak declared over by late July) and France (one), with treatment links to Germany, underscoring cross-border risks to neighbors like South Sudan. Rapid case growth and incomplete detection mean new reports from additional countries remain possible before year-end, though response efforts and surveillance upgrades could limit further spread.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions